{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:42:15Z","timestamp":1786725735387,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>\n                      Functioning neuroendocrine tumors (NETs) that do not respond to standard therapies are commonly considered for Peptide Receptor Radionuclide Therapy (PRRT). The benefit of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTATATE PRRT in patients with progressive metastatic NET was analyzed and survival in multi-organ involvement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Forty-one patients with refractory, progressive, or advanced symptomatic NETs, with or without previous treatment modalities were studied. They were treated with\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTATATE IV infusion 150 mCi per dose up to four cycles. Retrospectively, they were assessed for response to PRRT based on clinical, Imaging-Contrast CT\/\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTATATE PET-CT, and biochemical markers. After treatment, classification based on disease status, symptomatic improvement, and response to treatment based on Chromogranin A level was done. The organs involved and their respective survival benefits, as estimated by Kaplan Meier, were plotted for 60 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The mean serum Chromogranin A level at baseline was 2841 U\/ml (Median = 3150). The main site of primary NET was in the pancreas, and the most common site for metastases was the liver. Following PRRT, all patients, except one, reported an improvement in their baseline complaints. Most (82%) reported no new symptoms, and 50% had a reduction in serum Chromogranin A levels. Follow-up imaging showed regression in one patient, static tumor in 18, and progression in rest. Considering radiological and clinical responses, the overall benefit was noticed in 29 (70%) patients. Despite symptomatic improvement, there was no significant survival benefit for those with pancreatic, liver, or nodal metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>A majority of patients who were treated with PRRT demonstrated clinical, radiological as well as biochemical positive responses warranting an earlier consideration for this well-tolerated treatment modality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijem.ijem_372_23","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T02:07:05Z","timestamp":1735610825000},"page":"601-610","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Outcome of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Progressive Metastatic Neuroendocrine Tumors from a Tertiary Care Center"],"prefix":"10.4103","volume":"28","author":[{"given":"David","family":"Mathew","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Christian Medical College, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumya S.","family":"Sunny","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Christian Medical College, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Benjamin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Christian Medical College, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junita R.","family":"John","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Christian Medical College, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K.","family":"Jebasingh","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh T.","family":"Georgy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Christian Medical College, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Christian Medical College, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regi","family":"Oommen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Christian Medical College, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"R1-20241231","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00259-010-1610-2","article-title":"Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy","volume":"38","author":"Ezziddin","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R2-20241231","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/archsurg.2010.10","article-title":"Identification of unknown primary tumors in patients with neuroendocrine liver metastases","volume":"145","author":"Wang","year":"2010","journal-title":"Arch Surg"},{"key":"R3-20241231","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2016.57577","article-title":"Chromogranin A-unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls","volume":"12","author":"Gut","year":"2016","journal-title":"Arch Med Sci AMS"},{"key":"R4-20241231","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00259-013-2402-2","article-title":"Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours:Factors associated with response and suggestions for therapeutic sequence","volume":"40","author":"Campana","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R5-20241231","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1159\/000516015","article-title":"The state of peptide receptor radionuclide therapy and its sequencing among current therapeutic options for gastroenteropancreatic neuroendocrine tumors","volume":"111","author":"Raymond","year":"2021","journal-title":"Neuroendocrinology"},{"key":"R6-20241231","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2967\/jnumed.119.240911","article-title":"NANETS\/SNMMI consensus statement on patient selection and appropriate use of 177Lu-DOTATATE peptide receptor radionuclide therapy","volume":"61","author":"Hope","year":"2020","journal-title":"J Nucl Med"},{"key":"R7-20241231","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4103\/ijmpo.ijmpo_161_19","article-title":"Peptide receptor radionuclide therapy in the management of neuroendocrine tumors (Neoplasms). Fundamentals and salient clinical practice points for medical oncologists","volume":"40","author":"Basu","year":"2019","journal-title":"Indian J Med Paediatr Oncol"},{"key":"R8-20241231","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours:Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R9-20241231","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4103\/sajc.sajc_364_18","article-title":"Clinical and epidemiological profile of neuroendocrine tumors:An experience from a regional cancer center from Western India","volume":"8","author":"Kulkarni","year":"2019","journal-title":"South Asian J Cancer"},{"key":"R10-20241231","doi-asserted-by":"crossref","first-page":"e62487","DOI":"10.1371\/journal.pone.0062487","article-title":"The epidemiology of neuroendocrine tumors in Taiwan:A nation-wide cancer registry-based study","volume":"22","author":"Tsai","year":"2013","journal-title":"PLoS One"},{"key":"R11-20241231","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5005\/jp-journals-10002-1280","article-title":"Rising incidence of neuroendocrine tumors in Singapore:An epidemiological study","volume":"12","author":"Parameswaran","year":"2020","journal-title":"World J Endocr Surg"},{"key":"R12-20241231","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bpg.2013.01.006","article-title":"Epidemiology of gastroenteropancreatic neuroendocrine tumours","volume":"26","author":"Fraenkel","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R13-20241231","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1002\/ijc.30400","article-title":"The epidemiology of metastases in neuroendocrine tumors:Epidemiology of metastases","volume":"15","author":"Riihim\u00e4ki","year":"2016","journal-title":"Int J Cancer"},{"key":"R14-20241231","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/ERC-17-0269","article-title":"Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms:More flaws than fame","volume":"25","author":"Marotta","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"R15-20241231","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1210\/jc.2011-0666","article-title":"Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus","volume":"96","author":"Yao","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R16-20241231","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1530\/EC-18-0059","article-title":"Prognostic value of chromogranin A in patients with GET\/NEN in the pancreas and the small intestine","volume":"7","author":"Fuksiewicz","year":"2018","journal-title":"Endocr Connect"},{"key":"R17-20241231","first-page":"5661","article-title":"Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors","volume":"34","author":"Chou","year":"2014","journal-title":"Anticancer Res"},{"key":"R18-20241231","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1186\/s12885-019-6000-y","article-title":"Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET):Dosimetry, toxicity, efficacy, and survival","volume":"19","author":"Rudisile","year":"2019","journal-title":"BMC Cancer"},{"key":"R19-20241231","first-page":"347","article-title":"Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues","volume":"14","author":"Bodei","year":"2010","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R20-20241231","doi-asserted-by":"crossref","first-page":"7039","DOI":"10.18632\/oncotarget.12402","article-title":"Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity","volume":"24","author":"Werner","year":"2017","journal-title":"Oncotarget"},{"key":"R21-20241231","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1530\/ERC-16-0524","article-title":"Pitfalls in the response evaluation after peptide receptor radionuclide therapy with 177Lu-DOTA0, Tyr3]octreotate","volume":"24","author":"Brabander","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"R22-20241231","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1210\/jc.2018-01991","article-title":"Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors","volume":"104","author":"Zandee","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R23-20241231","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/RLU.0000000000001639","article-title":"Clinical response profile of metastatic\/advanced pulmonary neuroendocrine tumors to peptide receptor radionuclide therapy with 177Lu-DOTATATE","volume":"42","author":"Parghane","year":"2017","journal-title":"Clin Nucl Med"},{"key":"R24-20241231","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/MNM.0000000000000926","article-title":"Resistant functioning and\/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors:Efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting","volume":"39","author":"Kalshetty","year":"2018","journal-title":"Nucl Med Commun"},{"key":"R25-20241231","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000371807","article-title":"Prognostic significance of lymph node metastases in small intestinal neuroendocrine tumors","volume":"5","author":"Kim","year":"2015","journal-title":"Neuroendocrinology"},{"key":"R26-20241231","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/MPA.0000000000000921","article-title":"Lymph node metastasis in the prognosis of gastroenteropancreatic neuroendocrine tumors","volume":"46","author":"Martin","year":"2017","journal-title":"Pancreas"},{"key":"R27-20241231","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.4103\/0366-6999.171427","article-title":"Impact and clinical predictors of lymph node metastases in nonfunctional pancreatic neuroendocrine tumors","volume":"128","author":"Jiang","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"R28-20241231","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.athoracsur.2018.05.044","article-title":"Incidence and prognostic significance of carcinoid lymph node metastases","volume":"106","author":"Kneuertz","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"R29-20241231","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archsurg.2012.1261","article-title":"Lymph nodes and survival in pancreatic neuroendocrine tumors","volume":"147","author":"Krampitz","year":"2012","journal-title":"Arch Surg"},{"key":"R30-20241231","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00259-015-3190-7","article-title":"Long-term results of PRRT in advanced bronchopulmonary carcinoid","volume":"43","author":"Mariniello","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_372_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:25:04Z","timestamp":1786724704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_372_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_372_23","relation":{},"ISSN":["2230-8210","2230-9500"],"issn-type":[{"value":"2230-8210","type":"print"},{"value":"2230-9500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"2023-09-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}